Autopsy report · NCT03427073

A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

“to re-evaluate biomarker strategy for recruitment to Part 2”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 11 months before it stopped.
• 20 participants enrolled.
• Results were posted on the registry 2 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Almac Discovery

Sponsor type

Industry

Conditions

Solid Tumors; Ovarian Cancer

Interventions

ALM201

Participants

20

Sites

3

Countries

United Kingdom

Trials that died the same way

• Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD
  “challenge in recruitment” (57% match in meaning)
• Early Prevention of PTSD in Patients Within One Week of Acute Physical Trauma
  “Preliminary data analysis underway, will determine whether additional recruitment is necessary upon review of collected data.” (56% match in meaning)
• Digital Sedation: Virtual Reality Hypnosis During Colonoscopy
  “Recruitment too complicated during pandemics. Phase 2 of recruitment completed and enough data available.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.